BC Innovations | Nov 21, 2019
Distillery Therapeutics

Drug-loaded lipid nanoparticles targeting tumor-associated myeloid cells for glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting immunosuppressive tumor-associated myeloid cells (TAMCs) with drug-loaded anti-PD-L1 lipid nanoparticles could treat glioma, an indication in which TAMCs contribute up to 50% of the tumor mass. The nanoparticles,...
BC Innovations | May 9, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest inhibiting BARD1, BRCA1, CDK1 or CKD12 could help treat tamoxifen-resistant breast cancer. In tumor tissue from 27 recurrent breast cancer patients whose tumors became resistant...
BC Innovations | Aug 11, 2017
Tools & Techniques

K follows C in chemoproteomics

A year after publishing a map of druggable cysteines in the proteome, Ben Cravatt’s lab at Scripps has reported its chemoproteomics tools can also profile lysines. By identifying reactive lysines in dozens of proteins for...
BC Innovations | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

Infectious disease INDICATION: Viral infection Cell culture studies suggest the pan-caspase inhibitor emricasan, the generic antihelminthic niclosamide or CDK inhibitors could help treat Zika. In a Zika virus-infected human glioblastoma cell line, screening of 6,000...
BC Innovations | Sep 19, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Mesothelioma Cyclin dependent kinase 1 (CDK1; CDC2) Mouse and in vitro studies identified analogs of the bis(indolyl)imidazole alkaloid nortopsentin that could help treat diffuse malignant...
BC Week In Review | Oct 29, 2012
Clinical News

Dinaciclib: Phase IIb/III started

Ligand began a Phase IIb/III trial to evaluate dinaciclib in patients with refractory CLL. The trial start triggers a $2 million milestone payment from partner Merck under a deal to develop dinaciclib. Ligand said it...
BC Innovations | Aug 2, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Cyclin dependent kinase 1 (CDK1; CDC2); CDK2; phosphoinositide 3-kinase (PI3K) Mouse and cell culture studies suggest combined inhibition of CDK1 and CDK2 could...
BC Innovations | Apr 12, 2012
Cover Story

Targeting CDK in triple-negative breast cancer

A team at the University of California, San Francisco has found a dysregulated MYC pathway that underlies the majority of triple-negative breast cancers-a form of the disease with limited treatment options. 1 The researchers also...
BC Innovations | Apr 12, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Cyclin dependent kinase (CDK) Mouse and cell culture studies suggest CDK inhibitors could help treat triple-negative breast cancer. In five triple-negative human breast...
BC Week In Review | Nov 21, 2011
Clinical News

Dinaciclib regulatory update

Ligand disclosed in its 3Q11 earnings that FDA and the European Commission granted Orphan Drug designation for dinaciclib to treat chronic lymphocytic leukemia (CLL). The cyclin dependent kinase (CDK) inhibitor, which is partnered with Merck,...
Items per page:
1 - 10 of 12